Caracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018
125 páginas : gráficas
- Autores:
-
Sánchez Triana, Jhoan Nicolás
Cadena Romero, Nicolás
- Tipo de recurso:
- Trabajo de grado de pregrado
- Fecha de publicación:
- 2019
- Institución:
- Universidad de Ciencias Aplicadas y Ambientales U.D.C.A
- Repositorio:
- Repositorio Institucional UDCA
- Idioma:
- spa
- OAI Identifier:
- oai:repository.udca.edu.co:11158/1372
- Acceso en línea:
- https://repository.udca.edu.co/handle/11158/1372
- Palabra clave:
- Medicamentos - Efectos secundarios
Enzimas
Farmacovigilancia
Agalsidasa
Alfa Agalsidasa Beta
Alglucosidasa
Asparaginasa
Estreptoquinasa
Idursulfasa
Imiglucerasa
Laronidasa
Tenecteplasa
Inmunogenicidad
- Rights
- openAccess
- License
- Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales, 2019
| id |
RepoUDCA2_8bcfda56336dbb8d9f6e5507803a95a2 |
|---|---|
| oai_identifier_str |
oai:repository.udca.edu.co:11158/1372 |
| network_acronym_str |
RepoUDCA2 |
| network_name_str |
Repositorio Institucional UDCA |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Caracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018 |
| title |
Caracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018 |
| spellingShingle |
Caracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018 Medicamentos - Efectos secundarios Enzimas Farmacovigilancia Agalsidasa Alfa Agalsidasa Beta Alglucosidasa Asparaginasa Estreptoquinasa Idursulfasa Imiglucerasa Laronidasa Tenecteplasa Inmunogenicidad |
| title_short |
Caracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018 |
| title_full |
Caracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018 |
| title_fullStr |
Caracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018 |
| title_full_unstemmed |
Caracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018 |
| title_sort |
Caracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018 |
| dc.creator.fl_str_mv |
Sánchez Triana, Jhoan Nicolás Cadena Romero, Nicolás |
| dc.contributor.advisor.spa.fl_str_mv |
Sabogal Carmona, Juan Sebastián, dir. |
| dc.contributor.author.spa.fl_str_mv |
Sánchez Triana, Jhoan Nicolás Cadena Romero, Nicolás |
| dc.subject.lemb.spa.fl_str_mv |
Medicamentos - Efectos secundarios Enzimas Farmacovigilancia |
| topic |
Medicamentos - Efectos secundarios Enzimas Farmacovigilancia Agalsidasa Alfa Agalsidasa Beta Alglucosidasa Asparaginasa Estreptoquinasa Idursulfasa Imiglucerasa Laronidasa Tenecteplasa Inmunogenicidad |
| dc.subject.proposal.spa.fl_str_mv |
Agalsidasa Alfa Agalsidasa Beta Alglucosidasa Asparaginasa Estreptoquinasa Idursulfasa Imiglucerasa Laronidasa Tenecteplasa Inmunogenicidad |
| description |
125 páginas : gráficas |
| publishDate |
2019 |
| dc.date.accessioned.spa.fl_str_mv |
2019-04-25T15:10:21Z |
| dc.date.available.spa.fl_str_mv |
2019-04-25T15:10:21Z |
| dc.date.issued.spa.fl_str_mv |
2019 |
| dc.type.spa.fl_str_mv |
Trabajo de grado - Pregrado |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_7a1f |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.content.spa.fl_str_mv |
Text |
| dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/TP |
| format |
http://purl.org/coar/resource_type/c_7a1f |
| status_str |
publishedVersion |
| dc.identifier.uri.spa.fl_str_mv |
https://repository.udca.edu.co/handle/11158/1372 |
| dc.identifier.local.spa.fl_str_mv |
QF014 S15c 2019 (205475) |
| url |
https://repository.udca.edu.co/handle/11158/1372 |
| identifier_str_mv |
QF014 S15c 2019 (205475) |
| dc.language.iso.spa.fl_str_mv |
spa |
| language |
spa |
| dc.relation.references.spa.fl_str_mv |
Amorin, M. (2012). Mucopolisacaridosis de tipo I hurler: Informe de un caso. Archivos Argentinos De Pediatria, 110(5), 103-106. doi:10.5546/aap.2012.e103 Aronson, J. K. (2016). Meyler's side effects of drugs. Amsterdam: Elsevier. Banerjee, A., Banerjee, U. C., & Chisti, Y. (2004). Streptokinase—a clinically useful thrombolytic agent. Biotechnology Advances, 22(4), 287-307. doi:10.1016/j.biotechadv.2003.09.004 Benedí, J., & Gómez Del Río, M. Ángeles. (2006). Fármacos antineoplásicos (I). Farmacia Profesional, 20(2), 60-65. Retrieved from http://www.elsevier.es/esrevista-farmacia-profesional-3-articulo-farmacos-antineoplasicos-i--13084621 Biofactor GmbH. (2015). Streptokinase 1,500,000 iu - summary of product characteristics (SmPC) - (eMC). Retrieved from https://www.medicines.org.uk/emc/product/4256/smpc#AUTHDATE BIOMARIN PHARMACEUTICAL INC. (2008). Aldurazyme (laronidase) biomarin pharmaceutical inc. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/larobio043003LB. pdf BioMarin Pharmaceutical Inc. (2008). Aldurazyme epar product information es. Retrieved from https://www.ema.europa.eu/documents/productinformation/aldurazyme-epar-product-information_es.pdf Boehringer Ingelheim International GmbH. (2008). Metalyse epar product information en. Retrieved from https://www.ema.europa.eu/documents/product-information/metalyse-eparproduct-information_en.pdf Cacho-Díaz, B., Lorenzana-Mendoza, N. A., Reyes-Soto, G., Hernández-Estrada, A., Monroy-Sosa, A., Guraieb-Chahin, P., & Cantu-de-León, D. (2018). Lactate deshydrogenase as a pronostic marker in neoplastic meningitis. Journal of Clinical Neuroscience, 51, 39-42. doi:10.1016/j.jocn.2018.02.014 Carrascosa, J. M. (2012). Inmunogenicidad en terapia biológica. Implicaciones en Dermatología. Actas Dermo-Sifiliográficas, 104(6), 471-479. doi:10.1016/j.ad.2013.02.005 Retrieved from https://www.clinicalkey.es/playcontent/1-s2.0-S0001731013000999 Clínica universidad de Navarra. (2018a). ¿Qué es trombolítico? Retrieved from https://www.cun.es/diccionario-medico/terminos/trombolitico Clínica universidad de Navarra. (2018b). Diagnóstico y tratamiento del infarto de miocardio en la clínica. Retrieved from https://www.cun.es/enfermedadestratamientos/enfermedades/infarto-miocardio Consulta registro invima. Retrieved from http://consultaregistro.invima.gov.co:8082/Consultas/consultas/consreg_encab cum.jsp Dingman, R., & Balu-Iyer, S. V. (2018). Immunogenicity of protein pharmaceuticals doi:2131/10.1016/j.xphs.2018.12.014 Dingman, R., & Balu-Iyer, S. V. (2018). Immunogenicity of protein pharmaceuticals doi:2131/10.1016/j.xphs.2018.12.014 El-Gharbawy, A. H., Mackey, J., DeArmey, S., Westby, G., Grinnell, S. G., Malovrh, P., . . . Kishnani, P. S. (2011). An individually, modified approach to desensitize infants and young children with pompe disease, and significant reactions to alglucosidase alfa infusions doi:2131/10.1016/j.ymgme.2011.07.004 Fernandes, Q. (2016). MicroRNA: Defining a new niche in leukemia. Blood Reviews, 31(3), 129-138. doi:10.1016/j.blre.2016.11.003 García Díaz, J.D.|Mesa Latorre, J.M.|Corps Fernández, D.|Valbuena Parra, A. (2016). Enfermedades por depósito lisosomal. Medicine - Programa de Formación Médica Continuada Acreditado, 12(19), 1072-1081. doi:10.1016/j.med.2016.09.020 Retrieved from https://www.clinicalkey.es/playcontent/1-s2.0-S0304541216301664 Genzyme Europe, B. V. (2008). Fabrazyme epar product information es. Retrieved from https://www.ema.europa.eu/documents/product-information/fabrazymeepar-product-information_es.pdf Genzyme Europe, B. V. (2011). Myozyme epar product information es. Retrieved from https://www.ema.europa.eu/documents/product-information/myozymeepar-product-information_es.pdf Genzyme Ltd. (2018). Cerezyme epar product information es. Retrieved from https://www.ema.europa.eu/documents/product-information/cerezyme-eparproduct-information_es.pdf Genzyme, a Sanofi company (Sanofi-Aventis S. A). (2018). ¿Qué es la enfermedad de pompe? | pompe.es. Retrieved from https://www.pompe.es/es/hcp/que-es-la-enfermedad-de-pompe# Giugliani, R., Rojas, V. M., Martins, A. M., Valadares, E. R., Clarke, J. T. R., Góes, J. E. C., . . . Cox, G. F. (2009). A dose-optimization trial of laronidase (aldurazyme ®) in patients with mucopolysaccharidosis I. Molecular Genetics and Metabolism, 96(1), 13-19. doi:10.1016/j.ymgme.2008.10.009 Hollak, C. E. M., vom Dahl, S., Aerts, J. M. F. G., Belmatoug, N., Bembi, B., Cohen, Y., . . . Cox, T. M. (2010). Force majeure: Therapeutic measures in response to restricted supply of imiglucerase (cerezyme) for patients with gaucher disease. Blood Cells, Molecules and Diseases, 44(1), 41-47. doi:10.1016/j.bcmd.2009.09.006 INSERM US14. (a). Orphanet: Enfermedad de gaucher tipo 3. Retrieved from https://www.orpha.net/consor4.01/www/cgibin/Disease_Search.php?lng=ES&data_id=11104&Disease_Disease_Search_ diseaseGroup=Gaucher-tipo3&Disease_Disease_Search_diseaseType=Pat&Enfermedad(es)%2Fgrupo%2 0de%20enfermedades=Enfermedad-de-Gaucher-tipo3&title=Enfermedad%20de%20Gaucher%20tipo%203&search=Disease_Sear ch_Simple&fbclid=IwAR3paij394n1EbaXpd3C6cWMT6Gu3v7IRKTyOczyIfJiZl7Uhrewn5ic3E INSERM US14. (b). Orphanet: Mucopolisacaridosis tipo 1. Retrieved from https://www.orpha.net/consor4.01/www/cgibin/Disease_Search.php?lng=ES&data_id=132&Disease_Disease_Search_dis easeGroup=Mucopolisacaridosis-tipo1&Disease_Disease_Search_diseaseType=Pat&Enfermedad(es)/grupo%20de %20enfermedades=Mucopolisacaridosis-tipo1&title=Mucopolisacaridosis%20tipo%201&search=Disease_Search_Simple INSERM US14. (2001). Orphanet: Enfermedad de fabry. Retrieved from https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=324&lng=ES Kesselheim, A. S., Wang, B., Franklin, J. M., & Darrow, J. J. (2015). Trends in utilization of FDA expedited drug development and approval programs, 1987- 2014: Cohort study. BMJ : British Medical Journal, 351, h4633. doi:10.1136/bmj.h4633 Kim, H., Kim, D., Hong, J., Lee, K., Seo, J., & Oh, B. H.Structural insights of idursulfase beta. To be Published, doi:10.2210/pdb6ioz/pdb KIM, J., & PARK, H. (2012). Unilateral femoral arterial thrombosis in a dog with malignant mammary gland tumor: Clinical and thermographic findings, and successful treatment with local intra-arterial administration of streptokinase. Journal of Veterinary Medical Science, 74(5), 657-661. doi:10.1292/jvms.11- 0432 Kose, M. D., Canda, E., Kağnıcı, M., Uçar, S. K., Onay, H., Yıldırım Sozmen, E., . . . Çoker, M. (2018). Coexistence of gaucher disease and severe congenital neutropenia. Blood Cells, Molecules and Diseases, doi:10.1016/j.bcmd.2018.07.001 Kyriakopoulos, S., & Kontoravdi, C. (2013). Analysis of the landscape of biologically-derived pharmaceuticals in europe: Dominant production systems, molecule types on the rise and approval trends. European Journal of Pharmaceutical Sciences, 48(3), 428-441. doi:10.1016/j.ejps.2012.11.016 Marini, B. L., Perissinotti, A. J., Bixby, D. L., Brown, J., & Burke, P. W. (2017). Catalyzing improvements in ALL therapy with asparaginase. Blood Reviews, 31(5), 328-338. doi:10.1016/j.blre.2017.06.002 Moumneh, T., Penaloza, A., & Roy, P. M. (2018). Trombosis venosa profunda doi:2131/10.1016/S1636-5410(17)87867-3 Muenzer, J., Burton, B. K., Harmatz, P., Botha, J., & Kampmann, C. (2019). Evaluation of the long-term treatment effects of idursulfase using statistical modelling: Data from the hunter outcome survey (HOS) doi://doi.org/10.1016/j.ymgme.2018.12.261 Navarrete-Meneses, M. d. P., & Pérez-Vera, P. (2017). Alteraciones epigenéticas en leucemia linfoblástica aguda. Boletín Médico Del Hospital Infantil De México, 74(4), 243-264. doi:10.1016/j.bmhimx.2017.02.005 Organización Panamericana de la Salud. (2010). Red PARF documento técnico no. 5 buenas prácticas de farmacovigilancia para las américas. Retrieved from http://apps.who.int/medicinedocs/documents/s18625es/s18625es.pdf Pérez-López, J., Moltó-Abad, M., Muñoz-Delgado, C., Morales-Conejo, M., Ceberio-Hualde, L., & del Toro, M. (2018). Efficacy of idursulfase therapy in patients with mucopolysaccharidosis type II who initiated enzyme replacement therapy in adult age. A systematic review of the literature. Molecular Genetics and Metabolism, 124(3), 216-227. doi:10.1016/j.ymgme.2018.04.013 Pulido Pérez, A., & Suárez Fernández, R. (2014). Enfermedades bullosas doi:2131/10.1016/S0304-5412(14)70696-1 Ramaswami, U. (2011). Update on role of agalsidase alfa in management of fabry disease. Drug Design, Development and Therapy, 5, 155-173. doi:10.2147/DDDT.S11985 RESERVADOS, INSERM US14-- TODOS LOS DERECHOS.Orphanet: Mucopolisacaridosis tipo 2. Retrieved from https://www.orpha.net/consor4.01/www/cgibin/Disease_Search.php?lng=ES&data_id=131&Disease_Disease_Search_dis easeGroup=Hunter&Disease_Disease_Search_diseaseType=Pat&Enfermeda d(es)/grupo%20de%20enfermedades=Mucopolisacaridosis-tipo2&title=Mucopolisacaridosis%20tipo%202&search=Disease_Search_Simple Rodríguez Morales, I., Valdés, Y. C., & Proveyer Derich, S. (2004). Citostáticos: Medicamentos riesgosos. Revista Cubana De Medicina, 43(2-3), 0-0. Retrieved from http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S0034- 75232004000200009&lng=es&nrm=iso&tlng=es Sabogal Carmona, J. S., Díaz Rodríguez, E. A., Espinosa Espinosa, I. I. & Línea de Acción Medicamentos Seguros de Bogota. (2013). Fundamentos de farmacovigilancia. Retrieved from http://biblioteca.saludcapital.gov.co/img_upload/57c59a889ca266ee6533c26f9 70cb14a/documentos/FUNDAMENTOS_FARMACOVIG.pdf Sauna, Z. E., Lagassé, D., Pedras-Vasconcelos, J., Golding, B., & Rosenberg, A. S. (2018). Evaluating and mitigating the immunogenicity of therapeutic proteins doi:2131/10.1016/j.tibtech.2018.05.008 Schuller, Y., Arends, M., Körver, S., Langeveld, M., & Hollak, C. E. M. (2018). Adaptive pathway development for fabry disease: A clinical approach. Drug Discovery Today, 23(6), 1251-1257. doi:10.1016/j.drudis.2018.02.004 Shire Human Genetic Therapies, A B.Replagal epar product information es. Retrieved from https://www.ema.europa.eu/documents/productinformation/replagal-epar-product-information_es.pdf Shire Human Genetic Therapies, Inc. (2015). Elapraseinf. Retrieved from https://medsafe.govt.nz/profs/datasheet/e/elapraseinf.pdf Shrivastava, Abhinav|Khan, Abdul Arif|Khurshid, Mohsin|Kalam, Mohd Abul|Jain, Sudhir K.|Singhal, Pradeep K. (2015). Recent developments in l -asparaginase discovery and its potential as anticancer agent. Critical Reviews in Oncology and Hematology, 100, 1-10. doi:10.1016/j.critrevonc.2015.01.002 Sociedad Española de Medicina Interna. (2015). Embolia pulmonar. Retrieved from https://www.fesemi.org/informacion-pacientes/conozca-mejor-suenfermedad/embolia-pulmonar Tsuji, K., & Tsutani, K. (2008). Approval of new biopharmaceuticals 1999–2006: Comparison of the US, EU and japan situations. European Journal of Pharmaceutics and Biopharmaceutics, 68(3), 496-502. doi:10.1016/j.ejpb.2007.07.013 Universidad nacional autónoma de México. (2018). La medicina moderna (siglos xix y xx). Retrieved from http://bibliotecadigital.ilce.edu.mx/sites/ciencia/volumen3/ciencia3/154/html/sec _16.htm Vedder, A. C., Breunig, F., Donker-Koopman, W. E., Mills, K., Young, E., Winchester, B., . . . Hollak, C. E. M. (2008). Treatment of fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL3 doi:2131/10.1016/j.ymgme.2008.03.003 Vermeer, F. (2001). Thrombolytic therapy in patients of female gender doi:2131/10.1016/S0049-3848(01)00305-X VigiBase. (2018). Vigiaccess. Retrieved from http://www.vigiaccess.org/ Vizcaíno, M., Lopera, J. E., Martínez, L., De los Reyes, I., & Linares, A. (2016). Guía de atención integral para la detección oportuna, diagnóstico, tratamiento y seguimiento de leucemia linfoide aguda en niños, niñas y adolescentes. Revista Colombiana De Cancerología, 20(1), 37-39. doi:10.1016/j.rccan.2015.08.003 Wacker Biotech GmbH. (2016). Spectrila epar product information es. Retrieved from https://www.ema.europa.eu/documents/product-information/spectrilaepar-product-information_es.pdf WHO Collaborating Centre for Drug Statistics Methodology. (2009). WHOCC - ATC/DDD index. Retrieved from https://www.whocc.no/atc_ddd_index/ Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., . . . Wilson, M. (2018). DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Research, 46(D1), D1082. doi:10.1093/nar/gkx1037 Zimran, A., Morris, E., Mengel, E., Kaplan, P., Belmatoug, N., Hughes, D. A., . . . vom Dahl, S. (2009). The female gaucher patient: The impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells, Molecules and Diseases, 43(3), 264- 288. doi:10.1016/j.bcmd.2009.04.003 |
| dc.rights.spa.fl_str_mv |
Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales, 2019 |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0) |
| rights_invalid_str_mv |
Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales, 2019 https://creativecommons.org/licenses/by-nc-sa/4.0/ Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0) http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Bogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019 |
| dc.publisher.faculty.spa.fl_str_mv |
Facultad de Ciencias |
| dc.publisher.program.spa.fl_str_mv |
Química Farmacéutica |
| institution |
Universidad de Ciencias Aplicadas y Ambientales U.D.C.A |
| bitstream.url.fl_str_mv |
https://repository.udca.edu.co/bitstreams/5a3d4133-6ee3-4f1d-98d3-c12bcb5bca72/download https://repository.udca.edu.co/bitstreams/9e048c02-f052-4ba6-b6b0-7c1c253b079d/download https://repository.udca.edu.co/bitstreams/4fa1b5e8-a635-431c-8b72-37fcc2765155/download https://repository.udca.edu.co/bitstreams/50c25b97-4a76-4232-9111-eb619f8e9189/download |
| bitstream.checksum.fl_str_mv |
9b0cd359c9c845c7d0641c11af133c2c f661acf14bedbf9f5d13897a0387e751 7231fd3ff0b52dae8cd60c4e2f966f10 c63711d04308118f5cca3ce8ff94d965 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio - Universidad de Ciencias Aplicadas y Ambientales UDCA. |
| repository.mail.fl_str_mv |
bdigital@metabiblioteca.com |
| _version_ |
1818152485203738624 |
| spelling |
Sabogal Carmona, Juan Sebastián, dir.Sánchez Triana, Jhoan NicolásCadena Romero, Nicolás2019-04-25T15:10:21Z2019-04-25T15:10:21Z2019https://repository.udca.edu.co/handle/11158/1372QF014 S15c 2019 (205475)125 páginas : gráficasOne of the most important advances in modern medicine is the development of molecular biology with an emphasis on genetics, the advance has been so important that today enzymes can be isolated, such as agalsidase Alfa, agalsidase Beta, Alglucosidase, Asparaginase, Streptokinase, Idursulfase, Imiglucerase, Laronidase and Tenecteplase. These drugs are used for enzymatic, antineoplastic and thrombolytic replacement therapy, for which it is necessary to conduct a pharmacovigilance study, in which the different adverse reactions to them were analyzed. The information collected were 231 cases, in which they presented 4 PRM and 227 RAM, the highest incidence occurs in men, where a significant number of cases are in an age range between 0 to 5 years old. In most cases, reactions associated with an immune response were determined. 7Uno de los avances más importantes de la medicina moderna es el desarrollo de la biología molecular con énfasis en genética, el avance ha sido tan importante que hoy en día se pueden aislar enzimas, como lo son agalsidasa Alfa, agalsidasa Beta, Alglucosidasa, Asparaginasa, Estreptoquinasa, Idursulfasa, Imiglucerasa, Laronidasa y Tenecteplasa. Estos medicamentos son usados para terapia de reemplazo enzimático, antineoplásico y trombolítico, por lo cual es necesario realizar un estudio de farmacovigilancia, en el cual se analizó las diferentes reacciones adversas a estos. De acuerdo con la información recolectado se obtuvo 231 casos, en los cuales presentaron 4 PRM y 227 RAM, la mayor incidencia se presenta en hombres, donde una cantidad significativa de los casos se encuentran en un rango de edad entre 0 a 5 años, también en la mayoría de los casos se determinó reacciones asociadas a respuesta inmune.Incluye bibliografíaPregradoQuímico(a) Farmacéuticoapplication/pdfspaBogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019Facultad de CienciasQuímica FarmacéuticaDerechos Reservados - Universidad de Ciencias Aplicadas y Ambientales, 2019https://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccessAtribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)http://purl.org/coar/access_right/c_abf2Caracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018Trabajo de grado - Pregradohttp://purl.org/coar/resource_type/c_7a1finfo:eu-repo/semantics/bachelorThesisinfo:eu-repo/semantics/publishedVersionTexthttp://purl.org/redcol/resource_type/TPhttp://purl.org/coar/version/c_970fb48d4fbd8a85Medicamentos - Efectos secundariosEnzimasFarmacovigilanciaAgalsidasaAlfa Agalsidasa BetaAlglucosidasaAsparaginasaEstreptoquinasaIdursulfasaImiglucerasaLaronidasaTenecteplasaInmunogenicidadAmorin, M. (2012). Mucopolisacaridosis de tipo I hurler: Informe de un caso. Archivos Argentinos De Pediatria, 110(5), 103-106. doi:10.5546/aap.2012.e103Aronson, J. K. (2016). Meyler's side effects of drugs. Amsterdam: Elsevier.Banerjee, A., Banerjee, U. C., & Chisti, Y. (2004). Streptokinase—a clinically useful thrombolytic agent. Biotechnology Advances, 22(4), 287-307. doi:10.1016/j.biotechadv.2003.09.004Benedí, J., & Gómez Del Río, M. Ángeles. (2006). Fármacos antineoplásicos (I). Farmacia Profesional, 20(2), 60-65. Retrieved from http://www.elsevier.es/esrevista-farmacia-profesional-3-articulo-farmacos-antineoplasicos-i--13084621Biofactor GmbH. (2015). Streptokinase 1,500,000 iu - summary of product characteristics (SmPC) - (eMC). Retrieved from https://www.medicines.org.uk/emc/product/4256/smpc#AUTHDATEBIOMARIN PHARMACEUTICAL INC. (2008). Aldurazyme (laronidase) biomarin pharmaceutical inc. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/larobio043003LB. pdfBioMarin Pharmaceutical Inc. (2008). Aldurazyme epar product information es. Retrieved from https://www.ema.europa.eu/documents/productinformation/aldurazyme-epar-product-information_es.pdfBoehringer Ingelheim International GmbH. (2008). Metalyse epar product information en. Retrieved from https://www.ema.europa.eu/documents/product-information/metalyse-eparproduct-information_en.pdfCacho-Díaz, B., Lorenzana-Mendoza, N. A., Reyes-Soto, G., Hernández-Estrada, A., Monroy-Sosa, A., Guraieb-Chahin, P., & Cantu-de-León, D. (2018). Lactate deshydrogenase as a pronostic marker in neoplastic meningitis. Journal of Clinical Neuroscience, 51, 39-42. doi:10.1016/j.jocn.2018.02.014Carrascosa, J. M. (2012). Inmunogenicidad en terapia biológica. Implicaciones en Dermatología. Actas Dermo-Sifiliográficas, 104(6), 471-479. doi:10.1016/j.ad.2013.02.005 Retrieved from https://www.clinicalkey.es/playcontent/1-s2.0-S0001731013000999Clínica universidad de Navarra. (2018a). ¿Qué es trombolítico? Retrieved from https://www.cun.es/diccionario-medico/terminos/tromboliticoClínica universidad de Navarra. (2018b). Diagnóstico y tratamiento del infarto de miocardio en la clínica. Retrieved from https://www.cun.es/enfermedadestratamientos/enfermedades/infarto-miocardioConsulta registro invima. Retrieved from http://consultaregistro.invima.gov.co:8082/Consultas/consultas/consreg_encab cum.jspDingman, R., & Balu-Iyer, S. V. (2018). Immunogenicity of protein pharmaceuticals doi:2131/10.1016/j.xphs.2018.12.014Dingman, R., & Balu-Iyer, S. V. (2018). Immunogenicity of protein pharmaceuticals doi:2131/10.1016/j.xphs.2018.12.014El-Gharbawy, A. H., Mackey, J., DeArmey, S., Westby, G., Grinnell, S. G., Malovrh, P., . . . Kishnani, P. S. (2011). An individually, modified approach to desensitize infants and young children with pompe disease, and significant reactions to alglucosidase alfa infusions doi:2131/10.1016/j.ymgme.2011.07.004Fernandes, Q. (2016). MicroRNA: Defining a new niche in leukemia. Blood Reviews, 31(3), 129-138. doi:10.1016/j.blre.2016.11.003García Díaz, J.D.|Mesa Latorre, J.M.|Corps Fernández, D.|Valbuena Parra, A. (2016). Enfermedades por depósito lisosomal. Medicine - Programa de Formación Médica Continuada Acreditado, 12(19), 1072-1081. doi:10.1016/j.med.2016.09.020 Retrieved from https://www.clinicalkey.es/playcontent/1-s2.0-S0304541216301664Genzyme Europe, B. V. (2008). Fabrazyme epar product information es. Retrieved from https://www.ema.europa.eu/documents/product-information/fabrazymeepar-product-information_es.pdfGenzyme Europe, B. V. (2011). Myozyme epar product information es. Retrieved from https://www.ema.europa.eu/documents/product-information/myozymeepar-product-information_es.pdfGenzyme Ltd. (2018). Cerezyme epar product information es. Retrieved from https://www.ema.europa.eu/documents/product-information/cerezyme-eparproduct-information_es.pdfGenzyme, a Sanofi company (Sanofi-Aventis S. A). (2018). ¿Qué es la enfermedad de pompe? | pompe.es. Retrieved from https://www.pompe.es/es/hcp/que-es-la-enfermedad-de-pompe#Giugliani, R., Rojas, V. M., Martins, A. M., Valadares, E. R., Clarke, J. T. R., Góes, J. E. C., . . . Cox, G. F. (2009). A dose-optimization trial of laronidase (aldurazyme ®) in patients with mucopolysaccharidosis I. Molecular Genetics and Metabolism, 96(1), 13-19. doi:10.1016/j.ymgme.2008.10.009Hollak, C. E. M., vom Dahl, S., Aerts, J. M. F. G., Belmatoug, N., Bembi, B., Cohen, Y., . . . Cox, T. M. (2010). Force majeure: Therapeutic measures in response to restricted supply of imiglucerase (cerezyme) for patients with gaucher disease. Blood Cells, Molecules and Diseases, 44(1), 41-47. doi:10.1016/j.bcmd.2009.09.006INSERM US14. (a). Orphanet: Enfermedad de gaucher tipo 3. Retrieved from https://www.orpha.net/consor4.01/www/cgibin/Disease_Search.php?lng=ES&data_id=11104&Disease_Disease_Search_ diseaseGroup=Gaucher-tipo3&Disease_Disease_Search_diseaseType=Pat&Enfermedad(es)%2Fgrupo%2 0de%20enfermedades=Enfermedad-de-Gaucher-tipo3&title=Enfermedad%20de%20Gaucher%20tipo%203&search=Disease_Sear ch_Simple&fbclid=IwAR3paij394n1EbaXpd3C6cWMT6Gu3v7IRKTyOczyIfJiZl7Uhrewn5ic3EINSERM US14. (b). Orphanet: Mucopolisacaridosis tipo 1. Retrieved from https://www.orpha.net/consor4.01/www/cgibin/Disease_Search.php?lng=ES&data_id=132&Disease_Disease_Search_dis easeGroup=Mucopolisacaridosis-tipo1&Disease_Disease_Search_diseaseType=Pat&Enfermedad(es)/grupo%20de %20enfermedades=Mucopolisacaridosis-tipo1&title=Mucopolisacaridosis%20tipo%201&search=Disease_Search_SimpleINSERM US14. (2001). Orphanet: Enfermedad de fabry. Retrieved from https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=324&lng=ESKesselheim, A. S., Wang, B., Franklin, J. M., & Darrow, J. J. (2015). Trends in utilization of FDA expedited drug development and approval programs, 1987- 2014: Cohort study. BMJ : British Medical Journal, 351, h4633. doi:10.1136/bmj.h4633Kim, H., Kim, D., Hong, J., Lee, K., Seo, J., & Oh, B. H.Structural insights of idursulfase beta. To be Published, doi:10.2210/pdb6ioz/pdbKIM, J., & PARK, H. (2012). Unilateral femoral arterial thrombosis in a dog with malignant mammary gland tumor: Clinical and thermographic findings, and successful treatment with local intra-arterial administration of streptokinase. Journal of Veterinary Medical Science, 74(5), 657-661. doi:10.1292/jvms.11- 0432Kose, M. D., Canda, E., Kağnıcı, M., Uçar, S. K., Onay, H., Yıldırım Sozmen, E., . . . Çoker, M. (2018). Coexistence of gaucher disease and severe congenital neutropenia. Blood Cells, Molecules and Diseases, doi:10.1016/j.bcmd.2018.07.001Kyriakopoulos, S., & Kontoravdi, C. (2013). Analysis of the landscape of biologically-derived pharmaceuticals in europe: Dominant production systems, molecule types on the rise and approval trends. European Journal of Pharmaceutical Sciences, 48(3), 428-441. doi:10.1016/j.ejps.2012.11.016Marini, B. L., Perissinotti, A. J., Bixby, D. L., Brown, J., & Burke, P. W. (2017). Catalyzing improvements in ALL therapy with asparaginase. Blood Reviews, 31(5), 328-338. doi:10.1016/j.blre.2017.06.002Moumneh, T., Penaloza, A., & Roy, P. M. (2018). Trombosis venosa profunda doi:2131/10.1016/S1636-5410(17)87867-3Muenzer, J., Burton, B. K., Harmatz, P., Botha, J., & Kampmann, C. (2019). Evaluation of the long-term treatment effects of idursulfase using statistical modelling: Data from the hunter outcome survey (HOS) doi://doi.org/10.1016/j.ymgme.2018.12.261Navarrete-Meneses, M. d. P., & Pérez-Vera, P. (2017). Alteraciones epigenéticas en leucemia linfoblástica aguda. Boletín Médico Del Hospital Infantil De México, 74(4), 243-264. doi:10.1016/j.bmhimx.2017.02.005Organización Panamericana de la Salud. (2010). Red PARF documento técnico no. 5 buenas prácticas de farmacovigilancia para las américas. Retrieved from http://apps.who.int/medicinedocs/documents/s18625es/s18625es.pdfPérez-López, J., Moltó-Abad, M., Muñoz-Delgado, C., Morales-Conejo, M., Ceberio-Hualde, L., & del Toro, M. (2018). Efficacy of idursulfase therapy in patients with mucopolysaccharidosis type II who initiated enzyme replacement therapy in adult age. A systematic review of the literature. Molecular Genetics and Metabolism, 124(3), 216-227. doi:10.1016/j.ymgme.2018.04.013Pulido Pérez, A., & Suárez Fernández, R. (2014). Enfermedades bullosas doi:2131/10.1016/S0304-5412(14)70696-1Ramaswami, U. (2011). Update on role of agalsidase alfa in management of fabry disease. Drug Design, Development and Therapy, 5, 155-173. doi:10.2147/DDDT.S11985RESERVADOS, INSERM US14-- TODOS LOS DERECHOS.Orphanet: Mucopolisacaridosis tipo 2. Retrieved from https://www.orpha.net/consor4.01/www/cgibin/Disease_Search.php?lng=ES&data_id=131&Disease_Disease_Search_dis easeGroup=Hunter&Disease_Disease_Search_diseaseType=Pat&Enfermeda d(es)/grupo%20de%20enfermedades=Mucopolisacaridosis-tipo2&title=Mucopolisacaridosis%20tipo%202&search=Disease_Search_SimpleRodríguez Morales, I., Valdés, Y. C., & Proveyer Derich, S. (2004). Citostáticos: Medicamentos riesgosos. Revista Cubana De Medicina, 43(2-3), 0-0. Retrieved from http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S0034- 75232004000200009&lng=es&nrm=iso&tlng=esSabogal Carmona, J. S., Díaz Rodríguez, E. A., Espinosa Espinosa, I. I. & Línea de Acción Medicamentos Seguros de Bogota. (2013). Fundamentos de farmacovigilancia. Retrieved from http://biblioteca.saludcapital.gov.co/img_upload/57c59a889ca266ee6533c26f9 70cb14a/documentos/FUNDAMENTOS_FARMACOVIG.pdfSauna, Z. E., Lagassé, D., Pedras-Vasconcelos, J., Golding, B., & Rosenberg, A. S. (2018). Evaluating and mitigating the immunogenicity of therapeutic proteins doi:2131/10.1016/j.tibtech.2018.05.008Schuller, Y., Arends, M., Körver, S., Langeveld, M., & Hollak, C. E. M. (2018). Adaptive pathway development for fabry disease: A clinical approach. Drug Discovery Today, 23(6), 1251-1257. doi:10.1016/j.drudis.2018.02.004Shire Human Genetic Therapies, A B.Replagal epar product information es. Retrieved from https://www.ema.europa.eu/documents/productinformation/replagal-epar-product-information_es.pdfShire Human Genetic Therapies, Inc. (2015). Elapraseinf. Retrieved from https://medsafe.govt.nz/profs/datasheet/e/elapraseinf.pdfShrivastava, Abhinav|Khan, Abdul Arif|Khurshid, Mohsin|Kalam, Mohd Abul|Jain, Sudhir K.|Singhal, Pradeep K. (2015). Recent developments in l -asparaginase discovery and its potential as anticancer agent. Critical Reviews in Oncology and Hematology, 100, 1-10. doi:10.1016/j.critrevonc.2015.01.002Sociedad Española de Medicina Interna. (2015). Embolia pulmonar. Retrieved from https://www.fesemi.org/informacion-pacientes/conozca-mejor-suenfermedad/embolia-pulmonarTsuji, K., & Tsutani, K. (2008). Approval of new biopharmaceuticals 1999–2006: Comparison of the US, EU and japan situations. European Journal of Pharmaceutics and Biopharmaceutics, 68(3), 496-502. doi:10.1016/j.ejpb.2007.07.013Universidad nacional autónoma de México. (2018). La medicina moderna (siglos xix y xx). Retrieved from http://bibliotecadigital.ilce.edu.mx/sites/ciencia/volumen3/ciencia3/154/html/sec _16.htmVedder, A. C., Breunig, F., Donker-Koopman, W. E., Mills, K., Young, E., Winchester, B., . . . Hollak, C. E. M. (2008). Treatment of fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL3 doi:2131/10.1016/j.ymgme.2008.03.003Vermeer, F. (2001). Thrombolytic therapy in patients of female gender doi:2131/10.1016/S0049-3848(01)00305-XVigiBase. (2018). Vigiaccess. Retrieved from http://www.vigiaccess.org/Vizcaíno, M., Lopera, J. E., Martínez, L., De los Reyes, I., & Linares, A. (2016). Guía de atención integral para la detección oportuna, diagnóstico, tratamiento y seguimiento de leucemia linfoide aguda en niños, niñas y adolescentes. Revista Colombiana De Cancerología, 20(1), 37-39. doi:10.1016/j.rccan.2015.08.003Wacker Biotech GmbH. (2016). Spectrila epar product information es. Retrieved from https://www.ema.europa.eu/documents/product-information/spectrilaepar-product-information_es.pdfWHO Collaborating Centre for Drug Statistics Methodology. (2009). WHOCC - ATC/DDD index. Retrieved from https://www.whocc.no/atc_ddd_index/Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., . . . Wilson, M. (2018). DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Research, 46(D1), D1082. doi:10.1093/nar/gkx1037Zimran, A., Morris, E., Mengel, E., Kaplan, P., Belmatoug, N., Hughes, D. A., . . . vom Dahl, S. (2009). The female gaucher patient: The impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells, Molecules and Diseases, 43(3), 264- 288. doi:10.1016/j.bcmd.2009.04.003PublicationORIGINALCaracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D.pdfCaracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D.pdfapplication/pdf2852886https://repository.udca.edu.co/bitstreams/5a3d4133-6ee3-4f1d-98d3-c12bcb5bca72/download9b0cd359c9c845c7d0641c11af133c2cMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-814775https://repository.udca.edu.co/bitstreams/9e048c02-f052-4ba6-b6b0-7c1c253b079d/downloadf661acf14bedbf9f5d13897a0387e751MD52TEXTCaracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D.pdf.txtCaracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D.pdf.txtExtracted texttext/plain187690https://repository.udca.edu.co/bitstreams/4fa1b5e8-a635-431c-8b72-37fcc2765155/download7231fd3ff0b52dae8cd60c4e2f966f10MD53THUMBNAILCaracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D.pdf.jpgCaracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D.pdf.jpgGenerated Thumbnailimage/jpeg4111https://repository.udca.edu.co/bitstreams/50c25b97-4a76-4232-9111-eb619f8e9189/downloadc63711d04308118f5cca3ce8ff94d965MD5411158/1372oai:repository.udca.edu.co:11158/13722024-05-09 14:33:47.449https://creativecommons.org/licenses/by-nc-sa/4.0/Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales, 2019open.accesshttps://repository.udca.edu.coRepositorio - Universidad de Ciencias Aplicadas y Ambientales UDCA.bdigital@metabiblioteca.comTEEgT0JSQSAoVEFMIFkgQ09NTyBTRSBERUZJTkUgTcOBUyBBREVMQU5URSkgU0UgT1RPUkdBIEJBSk8gTE9TIFRFUk1JTk9TIERFIEVTVEEgTElDRU5DSUEgUMOaQkxJQ0EgREUgQ1JFQVRJVkUgQ09NTU9OUyAo4oCcTFBDQ+KAnSBPIOKAnExJQ0VOQ0lB4oCdKS4gTEEgT0JSQSBFU1TDgSBQUk9URUdJREEgUE9SIERFUkVDSE9TIERFIEFVVE9SIFkvVSBPVFJBUyBMRVlFUyBBUExJQ0FCTEVTLiBRVUVEQSBQUk9ISUJJRE8gQ1VBTFFVSUVSIFVTTyBRVUUgU0UgSEFHQSBERSBMQSBPQlJBIFFVRSBOTyBDVUVOVEUgQ09OIExBIEFVVE9SSVpBQ0nDk04gUEVSVElORU5URSBERSBDT05GT1JNSURBRCBDT04gTE9TIFTDiVJNSU5PUyBERSBFU1RBIExJQ0VOQ0lBIFkgREUgTEEgTEVZIERFIERFUkVDSE8gREUgQVVUT1IuCk1FRElBTlRFIEVMIEVKRVJDSUNJTyBERSBDVUFMUVVJRVJBIERFIExPUyBERVJFQ0hPUyBRVUUgU0UgT1RPUkdBTiBFTiBFU1RBIExJQ0VOQ0lBLCBVU1RFRCBBQ0VQVEEgWSBBQ1VFUkRBIFFVRURBUiBPQkxJR0FETyBFTiBMT1MgVEVSTUlOT1MgUVVFIFNFIFNFw5FBTEFOIEVOIEVMTEEuIEVMIExJQ0VOQ0lBTlRFIENPTkNFREUgQSBVU1RFRCBMT1MgREVSRUNIT1MgQ09OVEVOSURPUyBFTiBFU1RBIExJQ0VOQ0lBIENPTkRJQ0lPTkFET1MgQSBMQSBBQ0VQVEFDScOTTiBERSBTVVMgVEVSTUlOT1MgWSBDT05ESUNJT05FUy4KMS4gRGVmaW5pY2lvbmVzCmEuCU9icmEgQ29sZWN0aXZhIGVzIHVuYSBvYnJhLCB0YWwgY29tbyB1bmEgcHVibGljYWNpw7NuIHBlcmnDs2RpY2EsIHVuYSBhbnRvbG9nw61hLCBvIHVuYSBlbmNpY2xvcGVkaWEsIGVuIGxhIHF1ZSBsYSBvYnJhIGVuIHN1IHRvdGFsaWRhZCwgc2luIG1vZGlmaWNhY2nDs24gYWxndW5hLCBqdW50byBjb24gdW4gZ3J1cG8gZGUgb3RyYXMgY29udHJpYnVjaW9uZXMgcXVlIGNvbnN0aXR1eWVuIG9icmFzIHNlcGFyYWRhcyBlIGluZGVwZW5kaWVudGVzIGVuIHPDrSBtaXNtYXMsIHNlIGludGVncmFuIGVuIHVuIHRvZG8gY29sZWN0aXZvLiBVbmEgT2JyYSBxdWUgY29uc3RpdHV5ZSB1bmEgb2JyYSBjb2xlY3RpdmEgbm8gc2UgY29uc2lkZXJhcsOhIHVuYSBPYnJhIERlcml2YWRhIChjb21vIHNlIGRlZmluZSBhYmFqbykgcGFyYSBsb3MgcHJvcMOzc2l0b3MgZGUgZXN0YSBsaWNlbmNpYS4gYXF1ZWxsYSBwcm9kdWNpZGEgcG9yIHVuIGdydXBvIGRlIGF1dG9yZXMsIGVuIHF1ZSBsYSBPYnJhIHNlIGVuY3VlbnRyYSBzaW4gbW9kaWZpY2FjaW9uZXMsIGp1bnRvIGNvbiB1bmEgY2llcnRhIGNhbnRpZGFkIGRlIG90cmFzIGNvbnRyaWJ1Y2lvbmVzLCBxdWUgY29uc3RpdHV5ZW4gZW4gc8OtIG1pc21vcyB0cmFiYWpvcyBzZXBhcmFkb3MgZSBpbmRlcGVuZGllbnRlcywgcXVlIHNvbiBpbnRlZ3JhZG9zIGFsIHRvZG8gY29sZWN0aXZvLCB0YWxlcyBjb21vIHB1YmxpY2FjaW9uZXMgcGVyacOzZGljYXMsIGFudG9sb2fDrWFzIG8gZW5jaWNsb3BlZGlhcy4KYi4JT2JyYSBEZXJpdmFkYSBzaWduaWZpY2EgdW5hIG9icmEgYmFzYWRhIGVuIGxhIG9icmEgb2JqZXRvIGRlIGVzdGEgbGljZW5jaWEgbyBlbiDDqXN0YSB5IG90cmFzIG9icmFzIHByZWV4aXN0ZW50ZXMsIHRhbGVzIGNvbW8gdHJhZHVjY2lvbmVzLCBhcnJlZ2xvcyBtdXNpY2FsZXMsIGRyYW1hdGl6YWNpb25lcywg4oCcZmljY2lvbmFsaXphY2lvbmVz4oCdLCB2ZXJzaW9uZXMgcGFyYSBjaW5lLCDigJxncmFiYWNpb25lcyBkZSBzb25pZG/igJ0sIHJlcHJvZHVjY2lvbmVzIGRlIGFydGUsIHJlc8O6bWVuZXMsIGNvbmRlbnNhY2lvbmVzLCBvIGN1YWxxdWllciBvdHJhIGVuIGxhIHF1ZSBsYSBvYnJhIHB1ZWRhIHNlciB0cmFuc2Zvcm1hZGEsIGNhbWJpYWRhIG8gYWRhcHRhZGEsIGV4Y2VwdG8gYXF1ZWxsYXMgcXVlIGNvbnN0aXR1eWFuIHVuYSBvYnJhIGNvbGVjdGl2YSwgbGFzIHF1ZSBubyBzZXLDoW4gY29uc2lkZXJhZGFzIHVuYSBvYnJhIGRlcml2YWRhIHBhcmEgZWZlY3RvcyBkZSBlc3RhIGxpY2VuY2lhLiAoUGFyYSBldml0YXIgZHVkYXMsIGVuIGVsIGNhc28gZGUgcXVlIGxhIE9icmEgc2VhIHVuYSBjb21wb3NpY2nDs24gbXVzaWNhbCBvIHVuYSBncmFiYWNpw7NuIHNvbm9yYSwgcGFyYSBsb3MgZWZlY3RvcyBkZSBlc3RhIExpY2VuY2lhIGxhIHNpbmNyb25pemFjacOzbiB0ZW1wb3JhbCBkZSBsYSBPYnJhIGNvbiB1bmEgaW1hZ2VuIGVuIG1vdmltaWVudG8gc2UgY29uc2lkZXJhcsOhIHVuYSBPYnJhIERlcml2YWRhIHBhcmEgbG9zIGZpbmVzIGRlIGVzdGEgbGljZW5jaWEpLgpjLglMaWNlbmNpYW50ZSwgZXMgZWwgaW5kaXZpZHVvIG8gbGEgZW50aWRhZCB0aXR1bGFyIGRlIGxvcyBkZXJlY2hvcyBkZSBhdXRvciBxdWUgb2ZyZWNlIGxhIE9icmEgZW4gY29uZm9ybWlkYWQgY29uIGxhcyBjb25kaWNpb25lcyBkZSBlc3RhIExpY2VuY2lhLgpkLglBdXRvciBvcmlnaW5hbCwgZXMgZWwgaW5kaXZpZHVvIHF1ZSBjcmXDsyBsYSBPYnJhLgplLglPYnJhLCBlcyBhcXVlbGxhIG9icmEgc3VzY2VwdGlibGUgZGUgcHJvdGVjY2nDs24gcG9yIGVsIHLDqWdpbWVuIGRlIERlcmVjaG8gZGUgQXV0b3IgeSBxdWUgZXMgb2ZyZWNpZGEgZW4gbG9zIHTDqXJtaW5vcyBkZSBlc3RhIGxpY2VuY2lhCmYuCVVzdGVkLCBlcyBlbCBpbmRpdmlkdW8gbyBsYSBlbnRpZGFkIHF1ZSBlamVyY2l0YSBsb3MgZGVyZWNob3Mgb3RvcmdhZG9zIGFsIGFtcGFybyBkZSBlc3RhIExpY2VuY2lhIHkgcXVlIGNvbiBhbnRlcmlvcmlkYWQgbm8gaGEgdmlvbGFkbyBsYXMgY29uZGljaW9uZXMgZGUgbGEgbWlzbWEgcmVzcGVjdG8gYSBsYSBPYnJhLCBvIHF1ZSBoYXlhIG9idGVuaWRvIGF1dG9yaXphY2nDs24gZXhwcmVzYSBwb3IgcGFydGUgZGVsIExpY2VuY2lhbnRlIHBhcmEgZWplcmNlciBsb3MgZGVyZWNob3MgYWwgYW1wYXJvIGRlIGVzdGEgTGljZW5jaWEgcGVzZSBhIHVuYSB2aW9sYWNpw7NuIGFudGVyaW9yLgoyLiBEZXJlY2hvcyBkZSBVc29zIEhvbnJhZG9zIHkgZXhjZXBjaW9uZXMgTGVnYWxlcy4KTmFkYSBlbiBlc3RhIExpY2VuY2lhIHBvZHLDoSBzZXIgaW50ZXJwcmV0YWRvIGNvbW8gdW5hIGRpc21pbnVjacOzbiwgbGltaXRhY2nDs24gbyByZXN0cmljY2nDs24gZGUgbG9zIGRlcmVjaG9zIGRlcml2YWRvcyBkZWwgdXNvIGhvbnJhZG8geSBvdHJhcyBsaW1pdGFjaW9uZXMgbyBleGNlcGNpb25lcyBhIGxvcyBkZXJlY2hvcyBkZWwgYXV0b3IgYmFqbyBlbCByw6lnaW1lbiBsZWdhbCB2aWdlbnRlIG8gZGVyaXZhZG8gZGUgY3VhbHF1aWVyIG90cmEgbm9ybWEgcXVlIHNlIGxlIGFwbGlxdWUuCjMuIENvbmNlc2nDs24gZGUgbGEgTGljZW5jaWEuCkJham8gbG9zIHTDqXJtaW5vcyB5IGNvbmRpY2lvbmVzIGRlIGVzdGEgTGljZW5jaWEsIGVsIExpY2VuY2lhbnRlIG90b3JnYSBhIFVzdGVkIHVuYSBsaWNlbmNpYSBtdW5kaWFsLCBsaWJyZSBkZSByZWdhbMOtYXMsIG5vIGV4Y2x1c2l2YSB5IHBlcnBldHVhIChkdXJhbnRlIHRvZG8gZWwgcGVyw61vZG8gZGUgdmlnZW5jaWEgZGUgbG9zIGRlcmVjaG9zIGRlIGF1dG9yKSBwYXJhIGVqZXJjZXIgZXN0b3MgZGVyZWNob3Mgc29icmUgbGEgT2JyYSB0YWwgeSBjb21vIHNlIGluZGljYSBhIGNvbnRpbnVhY2nDs246CmEuCVJlcHJvZHVjaXIgbGEgT2JyYSwgaW5jb3Jwb3JhciBsYSBPYnJhIGVuIHVuYSBvIG3DoXMgT2JyYXMgQ29sZWN0aXZhcywgeSByZXByb2R1Y2lyIGxhIE9icmEgaW5jb3Jwb3JhZGEgZW4gbGFzIE9icmFzIENvbGVjdGl2YXM7CmIuCURpc3RyaWJ1aXIgY29waWFzIG8gZm9ub2dyYW1hcyBkZSBsYXMgT2JyYXMsIGV4aGliaXJsYXMgcMO6YmxpY2FtZW50ZSwgZWplY3V0YXJsYXMgcMO6YmxpY2FtZW50ZSB5L28gcG9uZXJsYXMgYSBkaXNwb3NpY2nDs24gcMO6YmxpY2EsIGluY2x1ecOpbmRvbGFzIGNvbW8gaW5jb3Jwb3JhZGFzIGVuIE9icmFzIENvbGVjdGl2YXMsIHNlZ8O6biBjb3JyZXNwb25kYTsKYy4JRGlzdHJpYnVpciBjb3BpYXMgZGUgbGFzIE9icmFzIERlcml2YWRhcyBxdWUgc2UgZ2VuZXJlbiwgZXhoaWJpcmxhcyBww7pibGljYW1lbnRlLCBlamVjdXRhcmxhcyBww7pibGljYW1lbnRlIHkvbyBwb25lcmxhcyBhIGRpc3Bvc2ljacOzbiBww7pibGljYS4KTG9zIGRlcmVjaG9zIG1lbmNpb25hZG9zIGFudGVyaW9ybWVudGUgcHVlZGVuIHNlciBlamVyY2lkb3MgZW4gdG9kb3MgbG9zIG1lZGlvcyB5IGZvcm1hdG9zLCBhY3R1YWxtZW50ZSBjb25vY2lkb3MgbyBxdWUgc2UgaW52ZW50ZW4gZW4gZWwgZnV0dXJvLiBMb3MgZGVyZWNob3MgYW50ZXMgbWVuY2lvbmFkb3MgaW5jbHV5ZW4gZWwgZGVyZWNobyBhIHJlYWxpemFyIGRpY2hhcyBtb2RpZmljYWNpb25lcyBlbiBsYSBtZWRpZGEgcXVlIHNlYW4gdMOpY25pY2FtZW50ZSBuZWNlc2FyaWFzIHBhcmEgZWplcmNlciBsb3MgZGVyZWNob3MgZW4gb3RybyBtZWRpbyBvIGZvcm1hdG9zLCBwZXJvIGRlIG90cmEgbWFuZXJhIHVzdGVkIG5vIGVzdMOhIGF1dG9yaXphZG8gcGFyYSByZWFsaXphciBvYnJhcyBkZXJpdmFkYXMuVG9kb3MgbG9zIGRlcmVjaG9zIG5vIG90b3JnYWRvcyBleHByZXNhbWVudGUgcG9yIGVsIExpY2VuY2lhbnRlIHF1ZWRhbiBwb3IgZXN0ZSBtZWRpbyByZXNlcnZhZG9zLCBpbmNsdXllbmRvIHBlcm8gc2luIGxpbWl0YXJzZSBhIGFxdWVsbG9zIHF1ZSBzZSBtZW5jaW9uYW4gZW4gbGFzIHNlY2Npb25lcyA0KGQpIHkgNChlKS4KNC4gUmVzdHJpY2Npb25lcy4KTGEgbGljZW5jaWEgb3RvcmdhZGEgZW4gbGEgYW50ZXJpb3IgU2VjY2nDs24gMyBlc3TDoSBleHByZXNhbWVudGUgc3VqZXRhIHkgbGltaXRhZGEgcG9yIGxhcyBzaWd1aWVudGVzIHJlc3RyaWNjaW9uZXM6CmEuCVVzdGVkIHB1ZWRlIGRpc3RyaWJ1aXIsIGV4aGliaXIgcMO6YmxpY2FtZW50ZSwgZWplY3V0YXIgcMO6YmxpY2FtZW50ZSwgbyBwb25lciBhIGRpc3Bvc2ljacOzbiBww7pibGljYSBsYSBPYnJhIHPDs2xvIGJham8gbGFzIGNvbmRpY2lvbmVzIGRlIGVzdGEgTGljZW5jaWEsIHkgVXN0ZWQgZGViZSBpbmNsdWlyIHVuYSBjb3BpYSBkZSBlc3RhIGxpY2VuY2lhIG8gZGVsIElkZW50aWZpY2Fkb3IgVW5pdmVyc2FsIGRlIFJlY3Vyc29zIGRlIGxhIG1pc21hIGNvbiBjYWRhIGNvcGlhIGRlIGxhIE9icmEgcXVlIGRpc3RyaWJ1eWEsIGV4aGliYSBww7pibGljYW1lbnRlLCBlamVjdXRlIHDDumJsaWNhbWVudGUgbyBwb25nYSBhIGRpc3Bvc2ljacOzbiBww7pibGljYS4gTm8gZXMgcG9zaWJsZSBvZnJlY2VyIG8gaW1wb25lciBuaW5ndW5hIGNvbmRpY2nDs24gc29icmUgbGEgT2JyYSBxdWUgYWx0ZXJlIG8gbGltaXRlIGxhcyBjb25kaWNpb25lcyBkZSBlc3RhIExpY2VuY2lhIG8gZWwgZWplcmNpY2lvIGRlIGxvcyBkZXJlY2hvcyBkZSBsb3MgZGVzdGluYXRhcmlvcyBvdG9yZ2Fkb3MgZW4gZXN0ZSBkb2N1bWVudG8uIE5vIGVzIHBvc2libGUgc3VibGljZW5jaWFyIGxhIE9icmEuIFVzdGVkIGRlYmUgbWFudGVuZXIgaW50YWN0b3MgdG9kb3MgbG9zIGF2aXNvcyBxdWUgaGFnYW4gcmVmZXJlbmNpYSBhIGVzdGEgTGljZW5jaWEgeSBhIGxhIGNsw6F1c3VsYSBkZSBsaW1pdGFjacOzbiBkZSBnYXJhbnTDrWFzLiBVc3RlZCBubyBwdWVkZSBkaXN0cmlidWlyLCBleGhpYmlyIHDDumJsaWNhbWVudGUsIGVqZWN1dGFyIHDDumJsaWNhbWVudGUsIG8gcG9uZXIgYSBkaXNwb3NpY2nDs24gcMO6YmxpY2EgbGEgT2JyYSBjb24gYWxndW5hIG1lZGlkYSB0ZWNub2zDs2dpY2EgcXVlIGNvbnRyb2xlIGVsIGFjY2VzbyBvIGxhIHV0aWxpemFjacOzbiBkZSBlbGxhIGRlIHVuYSBmb3JtYSBxdWUgc2VhIGluY29uc2lzdGVudGUgY29uIGxhcyBjb25kaWNpb25lcyBkZSBlc3RhIExpY2VuY2lhLiBMbyBhbnRlcmlvciBzZSBhcGxpY2EgYSBsYSBPYnJhIGluY29ycG9yYWRhIGEgdW5hIE9icmEgQ29sZWN0aXZhLCBwZXJvIGVzdG8gbm8gZXhpZ2UgcXVlIGxhIE9icmEgQ29sZWN0aXZhIGFwYXJ0ZSBkZSBsYSBvYnJhIG1pc21hIHF1ZWRlIHN1amV0YSBhIGxhcyBjb25kaWNpb25lcyBkZSBlc3RhIExpY2VuY2lhLiBTaSBVc3RlZCBjcmVhIHVuYSBPYnJhIENvbGVjdGl2YSwgcHJldmlvIGF2aXNvIGRlIGN1YWxxdWllciBMaWNlbmNpYW50ZSBkZWJlLCBlbiBsYSBtZWRpZGEgZGUgbG8gcG9zaWJsZSwgZWxpbWluYXIgZGUgbGEgT2JyYSBDb2xlY3RpdmEgY3VhbHF1aWVyIHJlZmVyZW5jaWEgYSBkaWNobyBMaWNlbmNpYW50ZSBvIGFsIEF1dG9yIE9yaWdpbmFsLCBzZWfDum4gbG8gc29saWNpdGFkbyBwb3IgZWwgTGljZW5jaWFudGUgeSBjb25mb3JtZSBsbyBleGlnZSBsYSBjbMOhdXN1bGEgNChjKS4KYi4JVXN0ZWQgbm8gcHVlZGUgZWplcmNlciBuaW5ndW5vIGRlIGxvcyBkZXJlY2hvcyBxdWUgbGUgaGFuIHNpZG8gb3RvcmdhZG9zIGVuIGxhIFNlY2Npw7NuIDMgcHJlY2VkZW50ZSBkZSBtb2RvIHF1ZSBlc3TDqW4gcHJpbmNpcGFsbWVudGUgZGVzdGluYWRvcyBvIGRpcmVjdGFtZW50ZSBkaXJpZ2lkb3MgYSBjb25zZWd1aXIgdW4gcHJvdmVjaG8gY29tZXJjaWFsIG8gdW5hIGNvbXBlbnNhY2nDs24gbW9uZXRhcmlhIHByaXZhZGEuIEVsIGludGVyY2FtYmlvIGRlIGxhIE9icmEgcG9yIG90cmFzIG9icmFzIHByb3RlZ2lkYXMgcG9yIGRlcmVjaG9zIGRlIGF1dG9yLCB5YSBzZWEgYSB0cmF2w6lzIGRlIHVuIHNpc3RlbWEgcGFyYSBjb21wYXJ0aXIgYXJjaGl2b3MgZGlnaXRhbGVzIChkaWdpdGFsIGZpbGUtc2hhcmluZykgbyBkZSBjdWFscXVpZXIgb3RyYSBtYW5lcmEgbm8gc2Vyw6EgY29uc2lkZXJhZG8gY29tbyBlc3RhciBkZXN0aW5hZG8gcHJpbmNpcGFsbWVudGUgbyBkaXJpZ2lkbyBkaXJlY3RhbWVudGUgYSBjb25zZWd1aXIgdW4gcHJvdmVjaG8gY29tZXJjaWFsIG8gdW5hIGNvbXBlbnNhY2nDs24gbW9uZXRhcmlhIHByaXZhZGEsIHNpZW1wcmUgcXVlIG5vIHNlIHJlYWxpY2UgdW4gcGFnbyBtZWRpYW50ZSB1bmEgY29tcGVuc2FjacOzbiBtb25ldGFyaWEgZW4gcmVsYWNpw7NuIGNvbiBlbCBpbnRlcmNhbWJpbyBkZSBvYnJhcyBwcm90ZWdpZGFzIHBvciBlbCBkZXJlY2hvIGRlIGF1dG9yLgpjLglTaSB1c3RlZCBkaXN0cmlidXllLCBleGhpYmUgcMO6YmxpY2FtZW50ZSwgZWplY3V0YSBww7pibGljYW1lbnRlIG8gZWplY3V0YSBww7pibGljYW1lbnRlIGVuIGZvcm1hIGRpZ2l0YWwgbGEgT2JyYSBvIGN1YWxxdWllciBPYnJhIERlcml2YWRhIHUgT2JyYSBDb2xlY3RpdmEsIFVzdGVkIGRlYmUgbWFudGVuZXIgaW50YWN0YSB0b2RhIGxhIGluZm9ybWFjacOzbiBkZSBkZXJlY2hvIGRlIGF1dG9yIGRlIGxhIE9icmEgeSBwcm9wb3JjaW9uYXIsIGRlIGZvcm1hIHJhem9uYWJsZSBzZWfDum4gZWwgbWVkaW8gbyBtYW5lcmEgcXVlIFVzdGVkIGVzdMOpIHV0aWxpemFuZG86IChpKSBlbCBub21icmUgZGVsIEF1dG9yIE9yaWdpbmFsIHNpIGVzdMOhIHByb3Zpc3RvIChvIHNldWTDs25pbW8sIHNpIGZ1ZXJlIGFwbGljYWJsZSksIHkvbyAoaWkpIGVsIG5vbWJyZSBkZSBsYSBwYXJ0ZSBvIGxhcyBwYXJ0ZXMgcXVlIGVsIEF1dG9yIE9yaWdpbmFsIHkvbyBlbCBMaWNlbmNpYW50ZSBodWJpZXJlbiBkZXNpZ25hZG8gcGFyYSBsYSBhdHJpYnVjacOzbiAodi5nLiwgdW4gaW5zdGl0dXRvIHBhdHJvY2luYWRvciwgZWRpdG9yaWFsLCBwdWJsaWNhY2nDs24pIGVuIGxhIGluZm9ybWFjacOzbiBkZSBsb3MgZGVyZWNob3MgZGUgYXV0b3IgZGVsIExpY2VuY2lhbnRlLCB0w6lybWlub3MgZGUgc2VydmljaW9zIG8gZGUgb3RyYXMgZm9ybWFzIHJhem9uYWJsZXM7IGVsIHTDrXR1bG8gZGUgbGEgT2JyYSBzaSBlc3TDoSBwcm92aXN0bzsgZW4gbGEgbWVkaWRhIGRlIGxvIHJhem9uYWJsZW1lbnRlIGZhY3RpYmxlIHksIHNpIGVzdMOhIHByb3Zpc3RvLCBlbCBJZGVudGlmaWNhZG9yIFVuaWZvcm1lIGRlIFJlY3Vyc29zIChVbmlmb3JtIFJlc291cmNlIElkZW50aWZpZXIpIHF1ZSBlbCBMaWNlbmNpYW50ZSBlc3BlY2lmaWNhIHBhcmEgc2VyIGFzb2NpYWRvIGNvbiBsYSBPYnJhLCBzYWx2byBxdWUgdGFsIFVSSSBubyBzZSByZWZpZXJhIGEgbGEgbm90YSBzb2JyZSBsb3MgZGVyZWNob3MgZGUgYXV0b3IgbyBhIGxhIGluZm9ybWFjacOzbiBzb2JyZSBlbCBsaWNlbmNpYW1pZW50byBkZSBsYSBPYnJhOyB5IGVuIGVsIGNhc28gZGUgdW5hIE9icmEgRGVyaXZhZGEsIGF0cmlidWlyIGVsIGNyw6lkaXRvIGlkZW50aWZpY2FuZG8gZWwgdXNvIGRlIGxhIE9icmEgZW4gbGEgT2JyYSBEZXJpdmFkYSAodi5nLiwgIlRyYWR1Y2Npw7NuIEZyYW5jZXNhIGRlIGxhIE9icmEgZGVsIEF1dG9yIE9yaWdpbmFsLCIgbyAiR3Vpw7NuIENpbmVtYXRvZ3LDoWZpY28gYmFzYWRvIGVuIGxhIE9icmEgb3JpZ2luYWwgZGVsIEF1dG9yIE9yaWdpbmFsIikuIFRhbCBjcsOpZGl0byBwdWVkZSBzZXIgaW1wbGVtZW50YWRvIGRlIGN1YWxxdWllciBmb3JtYSByYXpvbmFibGU7IGVuIGVsIGNhc28sIHNpbiBlbWJhcmdvLCBkZSBPYnJhcyBEZXJpdmFkYXMgdSBPYnJhcyBDb2xlY3RpdmFzLCB0YWwgY3LDqWRpdG8gYXBhcmVjZXLDoSwgY29tbyBtw61uaW1vLCBkb25kZSBhcGFyZWNlIGVsIGNyw6lkaXRvIGRlIGN1YWxxdWllciBvdHJvIGF1dG9yIGNvbXBhcmFibGUgeSBkZSB1bmEgbWFuZXJhLCBhbCBtZW5vcywgdGFuIGRlc3RhY2FkYSBjb21vIGVsIGNyw6lkaXRvIGRlIG90cm8gYXV0b3IgY29tcGFyYWJsZS4KZC4JUGFyYSBldml0YXIgdG9kYSBjb25mdXNpw7NuLCBlbCBMaWNlbmNpYW50ZSBhY2xhcmEgcXVlLCBjdWFuZG8gbGEgb2JyYSBlcyB1bmEgY29tcG9zaWNpw7NuIG11c2ljYWw6CmkuCVJlZ2Fsw61hcyBwb3IgaW50ZXJwcmV0YWNpw7NuIHkgZWplY3VjacOzbiBiYWpvIGxpY2VuY2lhcyBnZW5lcmFsZXMuIEVsIExpY2VuY2lhbnRlIHNlIHJlc2VydmEgZWwgZGVyZWNobyBleGNsdXNpdm8gZGUgYXV0b3JpemFyIGxhIGVqZWN1Y2nDs24gcMO6YmxpY2EgbyBsYSBlamVjdWNpw7NuIHDDumJsaWNhIGRpZ2l0YWwgZGUgbGEgb2JyYSB5IGRlIHJlY29sZWN0YXIsIHNlYSBpbmRpdmlkdWFsbWVudGUgbyBhIHRyYXbDqXMgZGUgdW5hIHNvY2llZGFkIGRlIGdlc3Rpw7NuIGNvbGVjdGl2YSBkZSBkZXJlY2hvcyBkZSBhdXRvciB5IGRlcmVjaG9zIGNvbmV4b3MgKHBvciBlamVtcGxvLCBTQVlDTyksIGxhcyByZWdhbMOtYXMgcG9yIGxhIGVqZWN1Y2nDs24gcMO6YmxpY2EgbyBwb3IgbGEgZWplY3VjacOzbiBww7pibGljYSBkaWdpdGFsIGRlIGxhIG9icmEgKHBvciBlamVtcGxvIFdlYmNhc3QpIGxpY2VuY2lhZGEgYmFqbyBsaWNlbmNpYXMgZ2VuZXJhbGVzLCBzaSBsYSBpbnRlcnByZXRhY2nDs24gbyBlamVjdWNpw7NuIGRlIGxhIG9icmEgZXN0w6EgcHJpbW9yZGlhbG1lbnRlIG9yaWVudGFkYSBwb3IgbyBkaXJpZ2lkYSBhIGxhIG9idGVuY2nDs24gZGUgdW5hIHZlbnRhamEgY29tZXJjaWFsIG8gdW5hIGNvbXBlbnNhY2nDs24gbW9uZXRhcmlhIHByaXZhZGEuCmlpLglSZWdhbMOtYXMgcG9yIEZvbm9ncmFtYXMuIEVsIExpY2VuY2lhbnRlIHNlIHJlc2VydmEgZWwgZGVyZWNobyBleGNsdXNpdm8gZGUgcmVjb2xlY3RhciwgaW5kaXZpZHVhbG1lbnRlIG8gYSB0cmF2w6lzIGRlIHVuYSBzb2NpZWRhZCBkZSBnZXN0acOzbiBjb2xlY3RpdmEgZGUgZGVyZWNob3MgZGUgYXV0b3IgeSBkZXJlY2hvcyBjb25leG9zIChwb3IgZWplbXBsbywgU0FZQ08pLCB1bmEgYWdlbmNpYSBkZSBkZXJlY2hvcyBtdXNpY2FsZXMgbyBhbGfDum4gYWdlbnRlIGRlc2lnbmFkbywgbGFzIHJlZ2Fsw61hcyBwb3IgY3VhbHF1aWVyIGZvbm9ncmFtYSBxdWUgVXN0ZWQgY3JlZSBhIHBhcnRpciBkZSBsYSBvYnJhICjigJx2ZXJzacOzbiBjb3ZlcuKAnSkgeSBkaXN0cmlidXlhLCBlbiBsb3MgdMOpcm1pbm9zIGRlbCByw6lnaW1lbiBkZSBkZXJlY2hvcyBkZSBhdXRvciwgc2kgbGEgY3JlYWNpw7NuIG8gZGlzdHJpYnVjacOzbiBkZSBlc2EgdmVyc2nDs24gY292ZXIgZXN0w6EgcHJpbW9yZGlhbG1lbnRlIGRlc3RpbmFkYSBvIGRpcmlnaWRhIGEgb2J0ZW5lciB1bmEgdmVudGFqYSBjb21lcmNpYWwgbyB1bmEgY29tcGVuc2FjacOzbiBtb25ldGFyaWEgcHJpdmFkYS4KZS4JR2VzdGnDs24gZGUgRGVyZWNob3MgZGUgQXV0b3Igc29icmUgSW50ZXJwcmV0YWNpb25lcyB5IEVqZWN1Y2lvbmVzIERpZ2l0YWxlcyAoV2ViQ2FzdGluZykuIFBhcmEgZXZpdGFyIHRvZGEgY29uZnVzacOzbiwgZWwgTGljZW5jaWFudGUgYWNsYXJhIHF1ZSwgY3VhbmRvIGxhIG9icmEgc2VhIHVuIGZvbm9ncmFtYSwgZWwgTGljZW5jaWFudGUgc2UgcmVzZXJ2YSBlbCBkZXJlY2hvIGV4Y2x1c2l2byBkZSBhdXRvcml6YXIgbGEgZWplY3VjacOzbiBww7pibGljYSBkaWdpdGFsIGRlIGxhIG9icmEgKHBvciBlamVtcGxvLCB3ZWJjYXN0KSB5IGRlIHJlY29sZWN0YXIsIGluZGl2aWR1YWxtZW50ZSBvIGEgdHJhdsOpcyBkZSB1bmEgc29jaWVkYWQgZGUgZ2VzdGnDs24gY29sZWN0aXZhIGRlIGRlcmVjaG9zIGRlIGF1dG9yIHkgZGVyZWNob3MgY29uZXhvcyAocG9yIGVqZW1wbG8sIEFjaW5wcm8pLCBsYXMgcmVnYWzDrWFzIHBvciBsYSBlamVjdWNpw7NuIHDDumJsaWNhIGRpZ2l0YWwgZGUgbGEgb2JyYSAocG9yIGVqZW1wbG8sIHdlYmNhc3QpLCBzdWpldGEgYSBsYXMgZGlzcG9zaWNpb25lcyBhcGxpY2FibGVzIGRlbCByw6lnaW1lbiBkZSBEZXJlY2hvIGRlIEF1dG9yLCBzaSBlc3RhIGVqZWN1Y2nDs24gcMO6YmxpY2EgZGlnaXRhbCBlc3TDoSBwcmltb3JkaWFsbWVudGUgZGlyaWdpZGEgYSBvYnRlbmVyIHVuYSB2ZW50YWphIGNvbWVyY2lhbCBvIHVuYSBjb21wZW5zYWNpw7NuIG1vbmV0YXJpYSBwcml2YWRhLgo1LiBSZXByZXNlbnRhY2lvbmVzLCBHYXJhbnTDrWFzIHkgTGltaXRhY2lvbmVzIGRlIFJlc3BvbnNhYmlsaWRhZC4KQSBNRU5PUyBRVUUgTEFTIFBBUlRFUyBMTyBBQ09SREFSQU4gREUgT1RSQSBGT1JNQSBQT1IgRVNDUklUTywgRUwgTElDRU5DSUFOVEUgT0ZSRUNFIExBIE9CUkEgKEVOIEVMIEVTVEFETyBFTiBFTCBRVUUgU0UgRU5DVUVOVFJBKSDigJxUQUwgQ1VBTOKAnSwgU0lOIEJSSU5EQVIgR0FSQU5Uw41BUyBERSBDTEFTRSBBTEdVTkEgUkVTUEVDVE8gREUgTEEgT0JSQSwgWUEgU0VBIEVYUFJFU0EsIElNUEzDjUNJVEEsIExFR0FMIE8gQ1VBTFFVSUVSQSBPVFJBLCBJTkNMVVlFTkRPLCBTSU4gTElNSVRBUlNFIEEgRUxMQVMsIEdBUkFOVMONQVMgREUgVElUVUxBUklEQUQsIENPTUVSQ0lBQklMSURBRCwgQURBUFRBQklMSURBRCBPIEFERUNVQUNJw5NOIEEgUFJPUMOTU0lUTyBERVRFUk1JTkFETywgQVVTRU5DSUEgREUgSU5GUkFDQ0nDk04sIERFIEFVU0VOQ0lBIERFIERFRkVDVE9TIExBVEVOVEVTIE8gREUgT1RSTyBUSVBPLCBPIExBIFBSRVNFTkNJQSBPIEFVU0VOQ0lBIERFIEVSUk9SRVMsIFNFQU4gTyBOTyBERVNDVUJSSUJMRVMgKFBVRURBTiBPIE5PIFNFUiBFU1RPUyBERVNDVUJJRVJUT1MpLiBBTEdVTkFTIEpVUklTRElDQ0lPTkVTIE5PIFBFUk1JVEVOIExBIEVYQ0xVU0nDk04gREUgR0FSQU5Uw41BUyBJTVBMw41DSVRBUywgRU4gQ1VZTyBDQVNPIEVTVEEgRVhDTFVTScOTTiBQVUVERSBOTyBBUExJQ0FSU0UgQSBVU1RFRC4KNi4gTGltaXRhY2nDs24gZGUgcmVzcG9uc2FiaWxpZGFkLgpBIE1FTk9TIFFVRSBMTyBFWElKQSBFWFBSRVNBTUVOVEUgTEEgTEVZIEFQTElDQUJMRSwgRUwgTElDRU5DSUFOVEUgTk8gU0VSw4EgUkVTUE9OU0FCTEUgQU5URSBVU1RFRCBQT1IgREHDkU8gQUxHVU5PLCBTRUEgUE9SIFJFU1BPTlNBQklMSURBRCBFWFRSQUNPTlRSQUNUVUFMLCBQUkVDT05UUkFDVFVBTCBPIENPTlRSQUNUVUFMLCBPQkpFVElWQSBPIFNVQkpFVElWQSwgU0UgVFJBVEUgREUgREHDkU9TIE1PUkFMRVMgTyBQQVRSSU1PTklBTEVTLCBESVJFQ1RPUyBPIElORElSRUNUT1MsIFBSRVZJU1RPUyBPIElNUFJFVklTVE9TIFBST0RVQ0lET1MgUE9SIEVMIFVTTyBERSBFU1RBIExJQ0VOQ0lBIE8gREUgTEEgT0JSQSwgQVVOIENVQU5ETyBFTCBMSUNFTkNJQU5URSBIQVlBIFNJRE8gQURWRVJUSURPIERFIExBIFBPU0lCSUxJREFEIERFIERJQ0hPUyBEQcORT1MuIEFMR1VOQVMgTEVZRVMgTk8gUEVSTUlURU4gTEEgRVhDTFVTScOTTiBERSBDSUVSVEEgUkVTUE9OU0FCSUxJREFELCBFTiBDVVlPIENBU08gRVNUQSBFWENMVVNJw5NOIFBVRURFIE5PIEFQTElDQVJTRSBBIFVTVEVELgo3LiBUw6lybWluby4KYS4JRXN0YSBMaWNlbmNpYSB5IGxvcyBkZXJlY2hvcyBvdG9yZ2Fkb3MgZW4gdmlydHVkIGRlIGVsbGEgdGVybWluYXLDoW4gYXV0b23DoXRpY2FtZW50ZSBzaSBVc3RlZCBpbmZyaW5nZSBhbGd1bmEgY29uZGljacOzbiBlc3RhYmxlY2lkYSBlbiBlbGxhLiBTaW4gZW1iYXJnbywgbG9zIGluZGl2aWR1b3MgbyBlbnRpZGFkZXMgcXVlIGhhbiByZWNpYmlkbyBPYnJhcyBEZXJpdmFkYXMgbyBDb2xlY3RpdmFzIGRlIFVzdGVkIGRlIGNvbmZvcm1pZGFkIGNvbiBlc3RhIExpY2VuY2lhLCBubyB2ZXLDoW4gdGVybWluYWRhcyBzdXMgbGljZW5jaWFzLCBzaWVtcHJlIHF1ZSBlc3RvcyBpbmRpdmlkdW9zIG8gZW50aWRhZGVzIHNpZ2FuIGN1bXBsaWVuZG8gw61udGVncmFtZW50ZSBsYXMgY29uZGljaW9uZXMgZGUgZXN0YXMgbGljZW5jaWFzLiBMYXMgU2VjY2lvbmVzIDEsIDIsIDUsIDYsIDcsIHkgOCBzdWJzaXN0aXLDoW4gYSBjdWFscXVpZXIgdGVybWluYWNpw7NuIGRlIGVzdGEgTGljZW5jaWEuCmIuCVN1amV0YSBhIGxhcyBjb25kaWNpb25lcyB5IHTDqXJtaW5vcyBhbnRlcmlvcmVzLCBsYSBsaWNlbmNpYSBvdG9yZ2FkYSBhcXXDrSBlcyBwZXJwZXR1YSAoZHVyYW50ZSBlbCBwZXLDrW9kbyBkZSB2aWdlbmNpYSBkZSBsb3MgZGVyZWNob3MgZGUgYXV0b3IgZGUgbGEgb2JyYSkuIE5vIG9ic3RhbnRlIGxvIGFudGVyaW9yLCBlbCBMaWNlbmNpYW50ZSBzZSByZXNlcnZhIGVsIGRlcmVjaG8gYSBwdWJsaWNhciB5L28gZXN0cmVuYXIgbGEgT2JyYSBiYWpvIGNvbmRpY2lvbmVzIGRlIGxpY2VuY2lhIGRpZmVyZW50ZXMgbyBhIGRlamFyIGRlIGRpc3RyaWJ1aXJsYSBlbiBsb3MgdMOpcm1pbm9zIGRlIGVzdGEgTGljZW5jaWEgZW4gY3VhbHF1aWVyIG1vbWVudG87IGVuIGVsIGVudGVuZGlkbywgc2luIGVtYmFyZ28sIHF1ZSBlc2EgZWxlY2Npw7NuIG5vIHNlcnZpcsOhIHBhcmEgcmV2b2NhciBlc3RhIGxpY2VuY2lhIG8gcXVlIGRlYmEgc2VyIG90b3JnYWRhICwgYmFqbyBsb3MgdMOpcm1pbm9zIGRlIGVzdGEgbGljZW5jaWEpLCB5IGVzdGEgbGljZW5jaWEgY29udGludWFyw6EgZW4gcGxlbm8gdmlnb3IgeSBlZmVjdG8gYSBtZW5vcyBxdWUgc2VhIHRlcm1pbmFkYSBjb21vIHNlIGV4cHJlc2EgYXRyw6FzLiBMYSBMaWNlbmNpYSByZXZvY2FkYSBjb250aW51YXLDoSBzaWVuZG8gcGxlbmFtZW50ZSB2aWdlbnRlIHkgZWZlY3RpdmEgc2kgbm8gc2UgbGUgZGEgdMOpcm1pbm8gZW4gbGFzIGNvbmRpY2lvbmVzIGluZGljYWRhcyBhbnRlcmlvcm1lbnRlLgo4LiBWYXJpb3MuCmEuCUNhZGEgdmV6IHF1ZSBVc3RlZCBkaXN0cmlidXlhIG8gcG9uZ2EgYSBkaXNwb3NpY2nDs24gcMO6YmxpY2EgbGEgT2JyYSBvIHVuYSBPYnJhIENvbGVjdGl2YSwgZWwgTGljZW5jaWFudGUgb2ZyZWNlcsOhIGFsIGRlc3RpbmF0YXJpbyB1bmEgbGljZW5jaWEgZW4gbG9zIG1pc21vcyB0w6lybWlub3MgeSBjb25kaWNpb25lcyBxdWUgbGEgbGljZW5jaWEgb3RvcmdhZGEgYSBVc3RlZCBiYWpvIGVzdGEgTGljZW5jaWEuCmIuCVNpIGFsZ3VuYSBkaXNwb3NpY2nDs24gZGUgZXN0YSBMaWNlbmNpYSByZXN1bHRhIGludmFsaWRhZGEgbyBubyBleGlnaWJsZSwgc2Vnw7puIGxhIGxlZ2lzbGFjacOzbiB2aWdlbnRlLCBlc3RvIG5vIGFmZWN0YXLDoSBuaSBsYSB2YWxpZGV6IG5pIGxhIGFwbGljYWJpbGlkYWQgZGVsIHJlc3RvIGRlIGNvbmRpY2lvbmVzIGRlIGVzdGEgTGljZW5jaWEgeSwgc2luIGFjY2nDs24gYWRpY2lvbmFsIHBvciBwYXJ0ZSBkZSBsb3Mgc3VqZXRvcyBkZSBlc3RlIGFjdWVyZG8sIGFxdcOpbGxhIHNlIGVudGVuZGVyw6EgcmVmb3JtYWRhIGxvIG3DrW5pbW8gbmVjZXNhcmlvIHBhcmEgaGFjZXIgcXVlIGRpY2hhIGRpc3Bvc2ljacOzbiBzZWEgdsOhbGlkYSB5IGV4aWdpYmxlLgpjLglOaW5nw7puIHTDqXJtaW5vIG8gZGlzcG9zaWNpw7NuIGRlIGVzdGEgTGljZW5jaWEgc2UgZXN0aW1hcsOhIHJlbnVuY2lhZGEgeSBuaW5ndW5hIHZpb2xhY2nDs24gZGUgZWxsYSBzZXLDoSBjb25zZW50aWRhIGEgbWVub3MgcXVlIGVzYSByZW51bmNpYSBvIGNvbnNlbnRpbWllbnRvIHNlYSBvdG9yZ2FkbyBwb3IgZXNjcml0byB5IGZpcm1hZG8gcG9yIGxhIHBhcnRlIHF1ZSByZW51bmNpZSBvIGNvbnNpZW50YS4KZC4JRXN0YSBMaWNlbmNpYSByZWZsZWphIGVsIGFjdWVyZG8gcGxlbm8gZW50cmUgbGFzIHBhcnRlcyByZXNwZWN0byBhIGxhIE9icmEgYXF1w60gbGljZW5jaWFkYS4gTm8gaGF5IGFycmVnbG9zLCBhY3VlcmRvcyBvIGRlY2xhcmFjaW9uZXMgcmVzcGVjdG8gYSBsYSBPYnJhIHF1ZSBubyBlc3TDqW4gZXNwZWNpZmljYWRvcyBlbiBlc3RlIGRvY3VtZW50by4gRWwgTGljZW5jaWFudGUgbm8gc2UgdmVyw6EgbGltaXRhZG8gcG9yIG5pbmd1bmEgZGlzcG9zaWNpw7NuIGFkaWNpb25hbCBxdWUgcHVlZGEgc3VyZ2lyIGVuIGFsZ3VuYSBjb211bmljYWNpw7NuIGVtYW5hZGEgZGUgVXN0ZWQuIEVzdGEgTGljZW5jaWEgbm8gcHVlZGUgc2VyIG1vZGlmaWNhZGEgc2luIGVsIGNvbnNlbnRpbWllbnRvIG11dHVvIHBvciBlc2NyaXRvIGRlbCBMaWNlbmNpYW50ZSB5IFVzdGVkLgoK |